RevOpsis says it is committed to the rapid discovery and development of novel multispecific therapies utilizing its modular ...

Waters added Wyatt Tehnology’s light scattering instruments to their portfolio last yeaf. According to Pittman, the company ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length ...

The market for next generation multispecific antibodies is experiencing remarkable growth and innovation, primarily driven by advancements in biotechnology. Building upon the foundation established by ...

Aptevo's Peter Pavlik, PhD, to chair a session on 'Bi and Multispecific Biologics' and will also give talk titled 'Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ ...

Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full data ...

Ramanath Bhandari, RevOpsis co-founder and CEO, commented: "RevOpsis is committed to the rapid discovery and development of novel multispecific therapies utilizing our modular RevModtm Platform ...

The 13 th Annual World Multispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover ...